These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 27873490)

  • 1. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
    Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
    Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
    Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K
    Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscape of Acquired Resistance to Osimertinib in
    Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
    Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC.
    Shiba-Ishii A; Isagawa T; Shiozawa T; Mato N; Nakagawa T; Takada Y; Hirai K; Hong J; Saitoh A; Takeda N; Niki T; Murakami Y; Matsubara D
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167249. PubMed ID: 38768929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
    Nelson-Taylor SK; Le AT; Yoo M; Schubert L; Mishall KM; Doak A; Varella-Garcia M; Tan AC; Doebele RC
    Mol Cancer Ther; 2017 Aug; 16(8):1623-1633. PubMed ID: 28500237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
    Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
    Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
    Tang Z; Jiang S; Du R; Petri ET; El-Telbany A; Chan PS; Kijima T; Dietrich S; Matsui K; Kobayashi M; Sasada S; Okamoto N; Suzuki H; Kawahara K; Iwasaki T; Nakagawa K; Kawase I; Christensen JG; Hirashima T; Halmos B; Salgia R; Boggon TJ; Kern JA; Ma PC
    Oncogene; 2009 Jan; 28(4):518-33. PubMed ID: 19015641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
    Santarpia L; Bottai G
    Curr Pharm Des; 2013; 19(5):864-82. PubMed ID: 22973956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
    Wang M; Naganna N; Sintim HO
    Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A secondary RET mutation in the activation loop conferring resistance to vandetanib.
    Nakaoku T; Kohno T; Araki M; Niho S; Chauhan R; Knowles PP; Tsuchihara K; Matsumoto S; Shimada Y; Mimaki S; Ishii G; Ichikawa H; Nagatoishi S; Tsumoto K; Okuno Y; Yoh K; McDonald NQ; Goto K
    Nat Commun; 2018 Feb; 9(1):625. PubMed ID: 29434222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
    Nishimura T; Nakamura H
    Adv Exp Med Biol; 2016; 926():115-137. PubMed ID: 27686809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.